IMRA - IMRA STOCK NEWS

Imara Inc. (Nasdaq: IMRA) announced significant advancements in the development of IMR-687, an oral treatment for sickle cell disease and beta-thalassemia. The company reported financial results for 2020, with a net loss of $49.2 million. IMR-687 is progressing through Phase 2b trials, with promising data from a Phase 2a trial indicating well-tolerated results and reduced vaso-occlusive crises. The company has raised $86.5 million in its IPO and expects research and development expenses between $50 million and $55 million in 2021. The leadership team has also expanded, enhancing operational capacity.

Imara Inc. (Nasdaq: IMRA) will host a conference call and webcast on March 5, 2021, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2020. The call aims to provide insights into recent business developments and offers investors an opportunity to understand the company's progress. Imara is focused on developing IMR-687, a promising treatment for sickle cell disease and beta-thalassemia.

Imara Inc. (Nasdaq: IMRA) announced that CEO Rahul Ballal, Ph.D., will participate in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, from 1:40-2:10 p.m. ET. This clinical-stage biotechnology company focuses on developing therapeutics for rare inherited genetic disorders of hemoglobin, particularly with its investigational drug IMR-687. A replay of the chat will be available on Imara's website under the 'Events and Presentations' section.

Imara Inc. has appointed Kenneth Attie, M.D., as Senior Vice President and Chief Medical Officer. Dr. Attie brings over 30 years of experience in the biopharmaceutical industry, notably from Acceleron Pharma, where he led clinical development for therapies approved for rare anemias. His leadership is expected to enhance the development of IMR-687, a treatment targeting hemoglobin disorders. IMR-687 is designed to be a disease-modifying oral therapy for sickle cell disease and beta-thalassemia, potentially improving patient outcomes significantly.

Imara Inc. (Nasdaq: IMRA) reported promising results from its Phase 2a clinical trial of IMR-687 for treating sickle cell disease (SCD). Patients treated with IMR-687 experienced a 25% reduction in vaso-occlusive crises compared to placebo. Biomarker data showed significant improvements in markers of hemolysis and inflammation. IMR-687 was well tolerated, with no serious adverse effects noted. Future updates from the ongoing studies, including the Phase 2a open label extension and Phase 2b trials, are expected in 2021, indicating a strong focus on advancing the treatment.

Imara Inc. (Nasdaq: IMRA) presented preliminary data from its ongoing Phase 2a open label extension trial for IMR-687, an investigational treatment for sickle cell disease (SCD). Case reports showed increased HbF percentage and F-cell counts after six months of treatment. Improvements in clinical outcomes and biomarkers were also noted. IMR-687 was well tolerated when used alone or with hydroxyurea. Two patients reported significant reductions in vaso-occlusive crises (VOCs), with one experiencing a 55% decrease. The company plans to report further data in Q1 2021.

Imara Inc. (Nasdaq: IMRA) announced the presentation of clinical data from its ongoing IMR-687 Phase 2a clinical trial at the virtual American Society of Hematology Annual Meeting on December 5-8, 2020. The presentation, focusing on the benefits and safety of long-term use of IMR-687 in adult sickle cell patients, is scheduled for on-demand viewing on December 6. Imara completed dosing in the Phase 2a clinical trial in Q3 2020 and plans to report top-line data by late Q4 2020, with additional data expected in Q1 2021.

Imara Inc. (Nasdaq: IMRA) has appointed Lynette Hopkinson as Senior Vice President of Regulatory Affairs, bringing 25 years of pharmaceutical and biotech experience. Hopkinson's expertise in global regulatory strategy is expected to advance IMR-687's development for treating sickle cell disease and beta-thalassemia. She previously oversaw regulatory strategies at Vertex Pharmaceuticals and played a significant role in clinical development. IMR-687 aims to reactivate fetal hemoglobin in patients, potentially lowering disease burden.

Imara Inc. has initiated patient dosing in its Phase 2b clinical trials for IMR-687 targeting sickle cell disease and beta-thalassemia. The European Commission granted Orphan Drug designation for IMR-687 in treating sickle cell disease. The company's third-quarter results showed a net loss of $12.4 million, or $0.72 per share, an increase from $6.6 million in Q3 2019. R&D expenses rose to $9.5 million, driven by clinical trial costs. Imara expects R&D costs to be between $32 million and $37 million for 2020, projecting sufficient cash to fund operations into mid-2022.